Latest Insider Transactions at Mirum Pharmaceuticals, Inc. (MIRM)
This section provides a real-time view of insider transactions for Mirum Pharmaceuticals, Inc. (MIRM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mirum Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mirum Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2022
|
Niall O'Donnell Director |
SELL
Open market or private sale
|
Indirect |
32,109
-1.84%
|
$610,071
$19.6 P/Share
|
|
Nov 11
2022
|
Niall O'Donnell Director |
SELL
Open market or private sale
|
Indirect |
174,121
-9.06%
|
$3,308,299
$19.99 P/Share
|
|
Nov 10
2022
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
82
+0.08%
|
$1,394
$17.05 P/Share
|
|
Nov 10
2022
|
Peter Radovich PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
292
+1.22%
|
$4,964
$17.05 P/Share
|
|
Nov 10
2022
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
660
+2.93%
|
$11,220
$17.05 P/Share
|
|
Nov 10
2022
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
49
+0.07%
|
$833
$17.05 P/Share
|
|
Nov 10
2022
|
Ian Clements Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
325
+1.07%
|
$5,525
$17.05 P/Share
|
|
Jun 06
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
38,478
-0.39%
|
$923,472
$24.95 P/Share
|
|
May 10
2022
|
Ian Clements Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,125
+3.65%
|
$14,625
$13.57 P/Share
|
|
May 10
2022
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+2.11%
|
$19,500
$13.57 P/Share
|
|
May 10
2022
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
807
+3.66%
|
$10,491
$13.57 P/Share
|
|
May 10
2022
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,454
+1.49%
|
$18,902
$13.57 P/Share
|
|
May 10
2022
|
Peter Radovich PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
1,169
+4.76%
|
$15,197
$13.57 P/Share
|
|
Jan 06
2022
|
Ian Clements Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+25.93%
|
-
|
|
Jan 06
2022
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+9.52%
|
-
|
|
Jan 06
2022
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+37.03%
|
-
|
|
Jan 06
2022
|
Peter Radovich PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+31.03%
|
-
|
|
Jan 06
2022
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+32.86%
|
-
|
|
Nov 26
2021
|
Ian Clements Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
750
+3.88%
|
$9,750
$13.9 P/Share
|
|
Nov 24
2021
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
7,000
+19.98%
|
$98,000
$14.4 P/Share
|
|
Nov 24
2021
|
Ian Clements Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
700
+3.78%
|
$9,800
$14.4 P/Share
|
|
Nov 10
2021
|
Ian Clements Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
458
+2.61%
|
$5,954
$13.52 P/Share
|
|
Nov 10
2021
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
753
+0.88%
|
$9,789
$13.52 P/Share
|
|
Nov 10
2021
|
Peter Radovich PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
958
+7.26%
|
$12,454
$13.52 P/Share
|
|
Nov 10
2021
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70
+0.15%
|
$910
$13.52 P/Share
|
|
Nov 10
2021
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
768
+6.86%
|
$9,984
$13.52 P/Share
|
|
Oct 01
2021
|
Edwin Jonathan Tucker Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,364
-2.89%
|
$25,916
$19.26 P/Share
|
|
Oct 01
2021
|
Peter Radovich PRESIDENT AND COO |
SELL
Open market or private sale
|
Direct |
1,364
-10.79%
|
$25,916
$19.26 P/Share
|
|
Oct 01
2021
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
961
-1.13%
|
$18,259
$19.26 P/Share
|
|
Oct 01
2021
|
Ian Clements Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,574
-8.64%
|
$29,906
$19.26 P/Share
|
|
Oct 01
2021
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,364
-12.37%
|
$25,916
$19.26 P/Share
|
|
Oct 01
2021
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,672
-14.87%
|
$69,768
$19.26 P/Share
|
|
Sep 29
2021
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+14.7%
|
-
|
|
Sep 29
2021
|
Peter Radovich PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+39.13%
|
-
|
|
Sep 29
2021
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+8.71%
|
-
|
|
Sep 29
2021
|
Ian Clements Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+33.96%
|
-
|
|
Sep 29
2021
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+42.41%
|
-
|
|
Sep 29
2021
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,875
+46.97%
|
-
|
|
Jul 09
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
99,325
-100.0%
|
$1,489,875
$15.81 P/Share
|
|
Jul 07
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,837
-6.44%
|
$102,555
$15.87 P/Share
|
|
Jul 06
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
49,239
-31.69%
|
$787,824
$16.2 P/Share
|
|
Jul 02
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,599
-6.38%
|
$180,183
$17.01 P/Share
|
|
May 10
2021
|
Ian Clements Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
981
+9.98%
|
$13,734
$14.62 P/Share
|
|
May 10
2021
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,259
+1.61%
|
$17,626
$14.62 P/Share
|
|
May 10
2021
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,453
+33.97%
|
$20,342
$14.62 P/Share
|
|
May 10
2021
|
Peter Radovich PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
1,006
+18.23%
|
$14,084
$14.62 P/Share
|
|
May 10
2021
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,483
+3.66%
|
$20,762
$14.62 P/Share
|
|
May 10
2021
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
699
+19.39%
|
$9,786
$14.62 P/Share
|
|
Mar 05
2021
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,082
+2.8%
|
$7,574
$7.7 P/Share
|
|
Dec 28
2020
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,167
+10.26%
|
$29,169
$7.7 P/Share
|